skip to main content

HCQ Screening Timeline — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardRheumatology PharmacologyHCQ Screening TimelineSCE Rheumatology

A patient has six disabling gout attacks in 12 months despite optimised urate-lowering therapy. NSAIDs and colchicine are contraindicated, and repeated corticosteroid courses are inappropriate. Canakinumab is selected for the current attack. Which schedule is authorised?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Give 150 mg subcutaneously once; responders may repeat after at least 12 weeks

Explanation lettering: B = shown as A · A = shown as B

B is correct. In the narrow authorised gout population, canakinumab is 150 mg subcutaneously as a single on-demand dose, preferably early in the attack. Responders who later require another dose must wait at least 12 weeks. Continuous monthly or weekly schedules belong to other autoinflammatory indications and are not gout prophylaxis; urate-lowering therapy still needs optimisation.

Reference: Ilaris 150 mg/mL solution for injection SmPC: https://www.medicines.org.uk/emc/product/8874/smpc